Pesquisar
Pharvaris NV
PHVSAdicionar à lista de desejos
33.070USD
-2.130-6.05%
Fechamento 09-23 16:00（ET）
2.30BValor de mercado
PerdaP/L TTM
Sobre o Pharvaris NV Empresa
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Pharvaris NV Perfil
Código da empresaPHVS
Nome da EmpresaPharvaris NV
Data de listagemFeb 05, 2021
CEOModig (Berndt B.A.E)
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 05
EndereçoEmmy Noetherweg 2
CidadeLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 BK
Telefone31712036410
Sitehttps://pharvaris.com/
Código da empresaPHVS
Data de listagemFeb 05, 2021
CEOModig (Berndt B.A.E)
Executivos da empresa Pharvaris NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Pharvaris NV?
Os cinco principais acionistas de Pharvaris NV são: Dr. Peng Lu, M.D., Ph.D.
Quantas instituições possuem ações da Pharvaris NV (PHVS)?
Em 2026Q1, 165 instituições possuíam ações da Pharvaris NV, com valor de mercado aproximado de 59.26M, representando 90.60% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -451327.00.